|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.85 DKK | -0.14% |
|
-3.11% | -0.97% |
| 06-14 | H. Lundbeck A/S Presents Preliminary Phase II Part A Data for Asedebart in Cushing's Disease | CI |
| 06-05 | H. Lundbeck A/S - Special Call |
Company Valuation: Lundbeck
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 25,433 | 31,719 | 39,416 | 41,398 | 40,562 | - | - |
| Change | - | 24.72% | 24.27% | 5.03% | -2.02% | - | - |
| Enterprise Value (EV) 1 | 27,464 | 31,008 | 51,598 | 49,619 | 44,660 | 40,531 | 36,481 |
| Change | - | 12.91% | 66.4% | -3.84% | -9.99% | -9.24% | -9.99% |
| P/E | 13.5x | 14.2x | 13x | 13.4x | 9.36x | 9.15x | 9.74x |
| PBR | 1.24x | 1.47x | 1.64x | 1.72x | 1.43x | 1.29x | 1.18x |
| PEG | - | 0.7x | 0.3x | 8.5x | 0.2x | 4.06x | -1.61x |
| Capitalization / Revenue | 1.39x | 1.59x | 1.79x | 1.68x | 1.58x | 1.58x | 1.63x |
| EV / Revenue | 1.51x | 1.56x | 2.34x | 2.01x | 1.74x | 1.57x | 1.46x |
| EV / EBITDA | 5.89x | 5.49x | 8.13x | 6.3x | 5.56x | 5.03x | 4.77x |
| EV / EBIT | 9.63x | 9.71x | 15.8x | 9.41x | 7.44x | 6.66x | 6.37x |
| EV / FCF | 10.2x | 8.66x | 18.7x | 10.2x | 7.95x | 6.49x | 6.52x |
| FCF Yield | 9.83% | 11.5% | 5.35% | 9.8% | 12.6% | 15.4% | 15.3% |
| Dividend per Share 2 | 0.58 | 0.7 | 0.95 | 1.15 | 1.475 | 1.508 | 1.462 |
| Rate of return | 2.23% | 2.14% | 2.3% | 2.66% | 3.5% | 3.58% | 3.47% |
| EPS 2 | 1.93 | 2.31 | 3.17 | 3.22 | 4.506 | 4.607 | 4.329 |
| Distribution rate | 30.1% | 30.3% | 30% | 35.7% | 32.7% | 32.7% | 33.8% |
| Net sales 1 | 18,246 | 19,912 | 22,004 | 24,630 | 25,704 | 25,735 | 24,960 |
| EBITDA 1 | 4,663 | 5,652 | 6,347 | 7,881 | 8,033 | 8,065 | 7,652 |
| EBIT 1 | 2,852 | 3,195 | 3,270 | 5,275 | 6,005 | 6,081 | 5,728 |
| Net income 1 | 1,916 | 2,290 | 3,143 | 3,192 | 4,710 | 4,807 | 4,665 |
| Net Debt 1 | 2,031 | -711 | 12,182 | 8,221 | 4,098 | -30.08 | -4,080 |
| Reference price 2 | 26.05 | 32.76 | 41.32 | 43.16 | 42.18 | 42.18 | 42.18 |
| Nbr of stocks (in thousands) | 992,840 | 992,840 | 992,011 | 991,227 | 991,227 | - | - |
| Announcement Date | 2/7/23 | 2/7/24 | 2/5/25 | 2/4/26 | - | - | - |
1DKK in Million2DKK
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 18.58x | 0.22x | 12.87x | 0.42% | 91.96B | ||
| 29.33x | 0.23x | 14.71x | 0.91% | 53.33B | ||
| 44.04x | 3.11x | 28.87x | 1.41% | 22.86B | ||
| 10.35x | 0.2x | 4.63x | 2.91% | 8.06B | ||
| 12.59x | 0.96x | 7.77x | 2.68% | 7.33B | ||
| 5.89x | 0.1x | 2.72x | 5.1% | 6.76B | ||
| 24.06x | 1.16x | 14.31x | 3% | 5.31B | ||
| 10.25x | 0.12x | 4.2x | 4.36% | 3.53B | ||
| 13.2x | - | - | 2.45% | 3.34B | ||
| Average | 18.70x | 0.76x | 11.26x | 2.58% | 22.5B | |
| Weighted average by Cap. | 23.23x | 0.60x | 14.22x | 1.17% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- HLUN B Stock
- LUN Stock
- Valuation Lundbeck
Select your edition
All financial news and data tailored to specific country editions
















